Intravenous immunoglobulin for the treatment of clostridium difficile associated diarrhoea-Experience at a UK Teaching Hospital

Paras N. Prasad; J. Lilleker; M. Cullen; J. Ramesh

Intravenous immunoglobulin for the treatment of clostridium difficile associated diarrhoea-Experience at a UK Teaching Hospital

Paras N. Prasad, J. Lilleker, M. Cullen, J. Ramesh

Division of Musculoskeletal & Dermatological Sciences

Research output: Contribution to journal › Article › peer-review

Abstract

Clostridium difficile associated diarrhoea (CDAD) is the most common cause of nosocomial diarrhoea worldwide. Recent epidemiology suggests increasing incidence in the UK with a 50-fold rise since 1990. Mortality has also risen due to the emergence of hypervirulent strains, particularly in the elderly. A poor IgG response to CD Toxin A has been shown to cause severe and recurrent CDAD. This led to the use of intravenous immunoglobulin (IVIG) for the treatment of CDAD but there is a relative paucity of evidence for its effectiveness in the literature.

Original language	English
Pages (from-to)	A26-A26
Journal	Gut
Volume	58
Publication status	Published - Apr 2009

Cite this

@article{f80e4e9cbb0c4c3cb9da89649e07b2fb,

title = "Intravenous immunoglobulin for the treatment of clostridium difficile associated diarrhoea-Experience at a UK Teaching Hospital",

abstract = "Clostridium difficile associated diarrhoea (CDAD) is the most common cause of nosocomial diarrhoea worldwide. Recent epidemiology suggests increasing incidence in the UK with a 50-fold rise since 1990. Mortality has also risen due to the emergence of hypervirulent strains, particularly in the elderly. A poor IgG response to CD Toxin A has been shown to cause severe and recurrent CDAD. This led to the use of intravenous immunoglobulin (IVIG) for the treatment of CDAD but there is a relative paucity of evidence for its effectiveness in the literature.",

author = "Prasad, {Paras N.} and J. Lilleker and M. Cullen and J. Ramesh",

year = "2009",

month = apr,

language = "English",

volume = "58",

pages = "A26--A26",

journal = "Gut",

issn = "0017-5749",

publisher = "BMJ ",

}

TY - JOUR

T1 - Intravenous immunoglobulin for the treatment of clostridium difficile associated diarrhoea-Experience at a UK Teaching Hospital

AU - Prasad, Paras N.

AU - Lilleker, J.

AU - Cullen, M.

AU - Ramesh, J.

PY - 2009/4

Y1 - 2009/4

N2 - Clostridium difficile associated diarrhoea (CDAD) is the most common cause of nosocomial diarrhoea worldwide. Recent epidemiology suggests increasing incidence in the UK with a 50-fold rise since 1990. Mortality has also risen due to the emergence of hypervirulent strains, particularly in the elderly. A poor IgG response to CD Toxin A has been shown to cause severe and recurrent CDAD. This led to the use of intravenous immunoglobulin (IVIG) for the treatment of CDAD but there is a relative paucity of evidence for its effectiveness in the literature.

AB - Clostridium difficile associated diarrhoea (CDAD) is the most common cause of nosocomial diarrhoea worldwide. Recent epidemiology suggests increasing incidence in the UK with a 50-fold rise since 1990. Mortality has also risen due to the emergence of hypervirulent strains, particularly in the elderly. A poor IgG response to CD Toxin A has been shown to cause severe and recurrent CDAD. This led to the use of intravenous immunoglobulin (IVIG) for the treatment of CDAD but there is a relative paucity of evidence for its effectiveness in the literature.

M3 - Article

SN - 0017-5749

VL - 58

SP - A26-A26

JO - Gut

JF - Gut

ER -

Intravenous immunoglobulin for the treatment of clostridium difficile associated diarrhoea-Experience at a UK Teaching Hospital

Abstract

Fingerprint

Cite this